. Author manuscript; available in PMC: 2023 May 27.

Published in final edited form as: J Nat Prod. 2022 Apr 15;85(5):1340–1350. doi: 10.1021/acs.jnatprod.2c00094

Table 4.

Antibacterial Activities of Ageliferin (13), Bromogeliferin (14), and Dibromoageliferin (15) against Multi-Drug-Resistant Gram-Positive and Gram-Negative Bacteria

strain (Gram +/−)	strain	resistance marker	13^a	14^a	15^a
E. coli (−)	ATCC 25922	susceptible	100	12.5	12.5
E. coli (−)	ATCC 35218	ESBL-producing	100	25	12.5
K. pneumoniae (−)	ATCC 700603	susceptible	>100	>100	12.5
K. pneumoniae (−)	id-146/19	carbapenemresistant	>100	>100	25
A. baumannii (−)	ATCC 19606	susceptible	>100	>100	100
A. baumannii (−)	id-261/16	carbapenemresistant	>100	100	100
P. aeruginosa (−)	ATCC 27853	susceptible	50	12.5	25
P. aeruginosa (−)	S-6065/06	carbapenemresistant	>100	50	25
E. faecalis (+)	ATCC 29212	susceptible	>100	>100	6.2
E. faecalis (+)	ATCC 51299	vancomycin resistant	>100	>100	6.2
S. aureus (+)	ATCC 25923	susceptible	>100	12.5	6.2
S. aureus (+)	ATCC 33591	oxacillinresisant	>100	12.5	6.2

Concentration in μM. ATCC, American Type Culture Collection; ESBL, β-lactamase broad-spectrum.